Clinical Trials Logo

Filter by:
NCT ID: NCT04850560 Recruiting - Clinical trials for Objective Response Rate

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

Start date: May 18, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in the treatment of relapse or refractory B cell lymphoma.

NCT ID: NCT04850053 Recruiting - Alzheimer's Disease Clinical Trials

Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis

Start date: August 26, 2020
Phase:
Study type: Observational

The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia. To perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.

NCT ID: NCT04850027 Recruiting - Rectal Cancer Clinical Trials

MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

To investigate the oncological outcome of lateral lymph node dissection in low rectal cancer based on MRI

NCT ID: NCT04850001 Recruiting - Clinical trials for Magnetic Resonance Imaging

Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study

Start date: September 10, 2020
Phase:
Study type: Observational

To investigate the cognitive decline after standard medical treatment without stenting in Asymptomatic Intracranial Stenosis patients and the underlying neural mechanism by fMRI.

NCT ID: NCT04849728 Recruiting - Clinical trials for NASH - Nonalcoholic Steatohepatitis

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NATiV3
Start date: August 19, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

NCT ID: NCT04849351 Recruiting - Follicular Lymphoma Clinical Trials

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Start date: April 14, 2021
Phase: Phase 2
Study type: Interventional

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)

NCT ID: NCT04849325 Recruiting - Clinical trials for Critical Limb Ischemia (CLI)

IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease

GENIUS
Start date: December 9, 2021
Phase: N/A
Study type: Interventional

A prospective, multi-center, randomized trial to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease.

NCT ID: NCT04849260 Recruiting - Clinical trials for Local Progression or Metastatic Melanoma With Failed First-line Treatment

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Start date: August 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The study will be divided into two stages: phase Ib and phase II. The safety and phase II recommended dose (RP2D) of Pexa-Vec combined with ZKAB001 in patients with local progression of failed first-line treatment or metastatic melanoma will be evaluated in phase Ib. Objective response rate (ORR) and progression-free survival (PFS) of ZKAB001 combined with RP2D's Pexa-Vec or ZKAB001 monotherapy in patients with local progression or metastatic melanoma will be evaluated in phase II.

NCT ID: NCT04849247 Recruiting - 68Ga-DOTA-FAPI Clinical Trials

68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI Theranostic Pair in Patients With Various Types of Cancer (Locally Advanced or Metastatic Cancer)

Start date: April 13, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I, first-in-human study to evaluate the safety and efficacy of the 68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI theranostic pair in patients with various types of cancer (locally advanced or metastatic cancer).

NCT ID: NCT04849104 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Cohort Study of Airway Microecology and the Pathogenesis and Evolution of Chronic Obstructive Pulmonary Disease

Start date: February 26, 2021
Phase:
Study type: Observational

This study will last for 5 years (2021.2.25-2025.12.31). 210 patients (70 cases in each group) will be enrolled in this study. Eight centers in China will participate in the study. The patients will be treated with bronchoscopy alveolar lavage, and 60 ml of bronchoalveolar lavage fluid will be collected for the next-generation sequencing of airway microorganisms. The patients will be followed up for 4 years to observe the changes of lung function, Fractional exhaled nitric oxide (FENO) and clinical symptoms.